Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Interaction between CDC6 and Tmod3 accelerates resistance to paclitaxel through focal adhesion assembly
Yue Liu1,2, Huirui Wang1, Jie Zhan1
1Key Laboratory of Natural Products & Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Abstract:
The widespread clinical application of paclitaxel (PTX) in cancer treatment has been significantly limited by the emergence of drug resistance and the presence of drug-tolerant persister cells. To systematically identify key regulators of this resistance, we conducted a genome-wide CRISPR/Cas9 knockout screen, which revealed that cell division cycle 6 (CDC6) is a critical determinant of cell adhesion-mediated PTX resistance. Furthermore, our results illustrate that CDC6, an essential DNA replication licensing factor, functions through a pathway distinct from previously well-characterized resistance mechanisms. Genetic depletion of CDC6 considerably sensitizes cells, markedly increasing PTX-induced cell death. In addition to its established role in chromosome stability, CDC6 physically interacts with tropomodulin-3 (Tmod3) in the cytoplasmic compartment. This interaction enhances CDC6 protein stability and drives drug resistance phenotypes through the regulation of actin cytoskeleton remodeling and facilitating focal adhesion assembly. In addition, combination treatment with PTX and actin filament inhibitors synergistically enhanced the antitumor efficacy both in vitro and in vivo. Overall, our studies elucidate the mechanisms through which CDC6 functions as a key regulator of PTX resistance and provide a potential therapeutic strategy to increase PTX efficacy through the modulation of the cytoskeletal-adhesion axis.
Insights
Cell division cycle 6 (CDC6) drives paclitaxel (PTX) resistance by regulating cell adhesion and the actin cytoskeleton. Depleting CDC6 sensitizes cancer cells to PTX, offering a new therapeutic strategy.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Paclitaxel (PTX) resistance and drug-tolerant persister cells limit its cancer treatment efficacy.
- Identifying novel regulators of PTX resistance is crucial for improving therapeutic outcomes.
Purpose of the Study:
- To systematically identify key regulators of paclitaxel resistance using a genome-wide screen.
- To elucidate the novel mechanisms by which CDC6 confers PTX resistance.
Main Methods:
- Genome-wide CRISPR/Cas9 knockout screen to identify resistance regulators.
- Genetic depletion of CDC6 and assessment of PTX sensitivity.
- Investigation of CDC6 interaction with Tmod3 and its role in cytoskeleton remodeling and focal adhesion assembly.
- Combination treatment studies with PTX and actin filament inhibitors in vitro and in vivo.
Main Results:
- Cell division cycle 6 (CDC6) was identified as a critical determinant of cell adhesion-mediated PTX resistance.
- CDC6 functions through a novel pathway, distinct from known resistance mechanisms.
- Genetic depletion of CDC6 significantly sensitized cells to PTX, increasing cell death.
- CDC6 interacts with Tmod3, enhancing its stability and promoting drug resistance via actin cytoskeleton remodeling and focal adhesion assembly.
- Combination therapy with PTX and actin inhibitors showed synergistic antitumor effects.
Conclusions:
- CDC6 is a key regulator of PTX resistance, operating through cytoskeletal and adhesion pathways.
- Targeting CDC6 or the cytoskeletal-adhesion axis presents a promising strategy to overcome PTX resistance and enhance cancer treatment efficacy.
Related Concept Videos
Drugs that Stabilize Microtubules
Microtubule Associated Proteins (MAPs)
Anaphase Promoting Complex
Destabilization of Microtubules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle

